[Skip to Navigation]
Sign In
February 12, 2021

Error in Discussion

JAMA Netw Open. 2021;4(2):e211376. doi:10.1001/jamanetworkopen.2021.1376

In the Original Investigation titled “Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial,”1 published January 13, 2021, there were errors in the Discussion section. The penultimate sentence of the first paragraph should have referred to a 0.8% weight loss among patients receiving placebo. The final sentence should have read that weight loss with bimagrumab was greater than the 1-year FDA threshold of 5% for registration of new medicines for treating obesity and overweight. This article has been corrected.1

Heymsfield  SB, Coleman  LA, Miller  R,  et al.  Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial.   JAMA Netw Open. 2021;4(1):e2033457. doi:10.1001/jamanetworkopen.2020.33457PubMedGoogle Scholar